Taysha Q1 FY26 net loss widens to $42.4 million; R&D expenses more than double to $33.8 million

Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc.

TSHA

0.00
  • Taysha Gene Therapies posted a first-quarter net loss of USD 42.4 million, or USD 0.12 per share, widening from USD 21.5 million, or USD 0.08 per share, a year earlier.
  • Research and development expense more than doubled to USD 33.8 million, while general and administrative costs rose to USD 9.7 million.
  • Cash and cash equivalents totaled USD 276.6 million at March 31, with cash runway expected to fund planned operating expenses into 2028.
  • FDA alignment was reaffirmed on TSHA-102 BLA pathway, including potential submission based on REVEAL pivotal trial six-month interim analysis; dosing in REVEAL and ASPIRE remained on track for completion in Q2 2026.
  • TSHA-102 maintained favorable tolerability with no treatment-related serious adverse events or dose-limiting toxicities as of May 2026 cutoff; BLA-enabling PPQ campaign started in April with completion expected in Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief on May 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.